Article Information
History
- August 3, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Steve M Taylor, MD MPH1,2,3,*,
- Sarah Korwa4,
- Angie Wu, MS2,
- Cynthia L Green, PhD2,5,
- Betsy Freedman1,
- Sheila Clapp, MBA2,
- Joseph Kipkoech Kirui, MSc4,
- Wendy P O’Meara, PhD1,3 and
- Festus M Njuguna, MBChB MMed PhD4,6
- 1Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA
- 2Duke Clinical Research Institute, Durham, NC, USA
- 3Duke Global Health Institute, Duke University, Durham, NC, USA
- 4Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya
- 5Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA
- 6Department of Child Health and Paediatrics, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya
- ↵*Corresponding author:
Steve M Taylor MD MPH, Box 102359 DUMC, 303 Research Drive, Sands #321A, Durham, NC 27710, steve.taylor{at}duke.edu
Posted August 03, 2022.
Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial
